In September of 2019, the United States Food and Drug Administration confirmed that trace amounts of a potential cancer-causing chemical was found in ranitidine, which is the generic name of the drug most commonly known as Zantac. This drug is now being potentially linked to the chemical N-nitrosodimethylamine (NDMA) which leads to an increased risk of a number of cancers. Immediately following this announcement a lawsuit against ranitidine has begun on behalf of those suffering from cancer who were prescribed Zantac or similar drugs containing ranitidine, and more lawsuits followed. Concerns over the drug started in the year prior when the only pharmacy Valisure discovered NDMA in ranitidine. This discovery occurred during routine testing. Valisure claimed from its independent testing that amounts of NMDA that were thousands of times higher than acceptable FDA limits were found in each test. Each test involved multiple manufacturers of ranitidine. Immediately after the F.D.A. made the announcement regarding the warnings on ranitidine, various companies began voluntarily recalling the drug. Shortly thereafter, lawsuit after lawsuit against ranitidine were being filed against a variety of international drug companies, including Amneal Pharmaceuticals, Apotex Corp., Aurobindo, Boehringer Ingelheim Pharmaceuticals, Lannett Company, Novitium Pharma, Perrigo Company, Pfizer, Sandoz, and Sanofi which produces Zantac. On February 6th, 2020, federal judges approved a motion to transfer and consolidate Zantac-related suits into basically one lawsuit against ranitidine. Initially 15 cases were consolidated into a multidistrict litigation, or MDL. This MDL includes both cases involving individuals regarding personal injuries as well as class actions seeking refunds. This process streamlines pretrial and the discovery process. In addition, this judgment allows for additional related lawsuits to join the litigation. There are currently over 100 cases pending in over 20 districts across the country, and there might be hundreds or even thousands of related suits that will get involved. The entirety of proceedings regarding the MDL will take place in the United States District Court for the Southern District of Florida. Once the discovery process is complete, U.S. District Judge Robin Rosenberg, who is presiding over the MDL, may select individual lawsuits to proceed. These suits will be initial trials that can help each side predict how other suits will fare. If these trials find in favor of the plaintiffs over the drug companies, the companies may seek a global settlement with consumers. Any global settlement will likely reduce the individual compensation, but will make compensation be paid out more quickly. Those consumers of Zantac and other ranitidine drugs who were also diagnosed with cancer are encouraged to contact an attorney about possible legal proceedings against the drug manufacturers.